Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYBB | P04839 | 1/20 | 0.66 |
| ▸ | NOX5 | Q96PH1 | 1/20 | 0.66 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.66 |
| ▸ | DUOX2 | Q9NRD8 | 1/20 | 0.66 |
| ▸ | DUOX1 | Q9NRD9 | 1/20 | 0.66 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.50 |
| ▸ | PKM | P14618 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29490371 | 1.00 | CYBB (0.66) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL15313075 | 0.85 | CYBB (0.69) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4941814 | 0.80 | KDM1A (0.66) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL16560732 | 0.80 | CYBB (0.63) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL29368383 | 0.79 | CYBB (1.00) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL2027831 | 0.79 | CYBB (1.00) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4918509 | 0.77 | CYBB (0.57) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4930461 | 0.77 | CYBB (0.57) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL17210872 | 0.74 | CYBB (0.67) | CYBBNOX5NOX4DUOX2DUOX1 | |
| SCHEMBL4922738 | 0.72 | ALDH1A1 (0.64) | ALDH1A1NPSR1PKMTSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | EMORY UNIVERSITY (US) | 2025-03-04 | — | — | US | claimed |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | ELECTROPHORETICS LIMITED (GB) | 2016-12-08 | — | — | US | disclosed |
| EP-1756113-B1 | COMPOUNDS CONTAINING A N-HETEROARYL MOIETY LINKED TO FUSED RING MOIETIES FOR THE INHIBITION OF NAD(P)H OXIDASES AND PLATELET ACTIVATION | VASOPHARM GMBH (DE) | 2014-05-07 | — | — | EP | disclosed |
| US-20120315303-A1 | METHODS AND INTRAVASCULAR TREATMENT DEVICES USING PACLITAXEL FOR TREATMENT OF ATHEROSCLEROSIS | MEDTRONIC VASCULAR, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-20120315303-A1 | METHODS AND INTRAVASCULAR TREATMENT DEVICES USING PACLITAXEL FOR TREATMENT OF ATHEROSCLEROSIS | MEDTRONIC VASCULAR, INC. (US) | 2012-12-13 | — | — | US | disclosed |
| US-8236809-B2 | Substituted 1,2,3-triazolopyrimidines for the inhibition of NAD(P)H oxidases and platelet activation | VASOPHARM GMBH (DE) | 2012-08-07 | — | — | US | disclosed |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | VASOPHARM GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| EP-1598354-A1 | Compounds containing a N-heteroaryl moiety linked to fused ring moieties for the inhibition of NAD(P)H oxidases and platelet activation | Vasopharm Biotech GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120315303-A1 | METHODS AND INTRAVASCULAR TREATMENT DEVICES USING PACLITAXEL FOR TREATMENT OF ATHEROSCLEROSIS | PCSK9, PLAT, PCSK7 | CYBB 1629/4885NOX5 2788/4885NOX4 622/4885 |
| US-20160354375-A1 | CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS TAUOPATHIES | CSNK1G1, CSNK1A1, CSNK1D | CYBB 4563/4885NOX5 4744/4885NOX4 4499/4885 |
| US-12239655-B2 | Combined modalities for nucleosides and/or NADPH oxidase (NOX) inhibitors as myeloid-specific antiviral agents | NOX1, NOX3, NOX4 | CYBB 6/4885NOX5 4/4885NOX4 3/4885 |
| US-20080044354-A1 | Compounds Containing a N-Heteroaryl Moiety Linked to Fused Ring Moieties for the Inhibition of Nad(P)H Oxidases and Platelet Activation | NQO1, CYBB, NADK | CYBB 2/4885NOX5 4/4885NOX4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.